{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:54:06Z","timestamp":1791536046974,"version":"4.3.4"},"reference-count":259,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012155","name":"National Institute for Medical Research Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bbcan.2026.189552","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:22:54Z","timestamp":1771374174000},"page":"189552","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Expanding the therapeutic applications of PARP inhibitors in cancer by targeting receptor tyrosine kinases"],"prefix":"10.1016","volume":"1881","author":[{"given":"Amirsajad","family":"Jafari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Moosavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omidreza","family":"Firuzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0005","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13045-024-01640-8","article-title":"Global burden of cancer and associated risk factors in 204 countries and territories, 1980-2021: a systematic analysis for the GBD 2021","volume":"17","author":"Wu","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189552_bb0010","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189552_bb0015","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung cancer: current status and future trends","volume":"20","author":"Leiter","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189552_bb0020","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41576-024-00796-w","article-title":"Genomic landscape of cancer in racially and ethnically diverse populations","volume":"26","author":"Thomas","year":"2025","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.bbcan.2026.189552_bb0025","doi-asserted-by":"crossref","DOI":"10.1177\/20503121211034366","article-title":"New approaches and procedures for cancer treatment: current perspectives","volume":"9","author":"Debela","year":"2021","journal-title":"SAGE Open Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0030","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41420-025-02418-8","article-title":"Perspectives on cancer therapy\u2014synthetic lethal precision medicine strategies, molecular mechanisms, therapeutic targets and current technical challenges","volume":"11","author":"Peng","year":"2025","journal-title":"Cell Death Dis."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189552_bb0035","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","article-title":"Molecular targeted therapy for anticancer treatment","volume":"54","author":"Min","year":"2022","journal-title":"Exp. Mol. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41392-025-02161-7","article-title":"Oncogenic gene fusions in cancer: from biology to therapy","volume":"10","author":"Liu","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0045","first-page":"1","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189552_bb0050","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.3390\/biomedicines10092113","article-title":"Targeting tyrosine kinases in ovarian cancer: small molecule inhibitor and monoclonal antibody, where are we now?","volume":"10","author":"Rendell","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.bbcan.2026.189552_bb0055","series-title":"Tumor Targeting. Organelle and Molecular Targeting","first-page":"153","author":"Pan","year":"2021"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189552_bb0060","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.3390\/ijms25105489","article-title":"Kinase inhibitors and kinase-targeted cancer therapies: recent advances and future perspectives","volume":"25","author":"Li","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189552_bb0065","first-page":"37","article-title":"Small molecule therapeutics in breast cancer: current approaches and future directions","author":"Yukta","year":"2025","journal-title":"Small Mol. Cancer Treatm."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189552_bb0070","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1158\/2159-8290.CD-21-0212","article-title":"Independent drug action in combination therapy: implications for precision oncology","volume":"12","author":"Plana","year":"2022","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0075","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-cancerbio-061421-020411","article-title":"Rationales for combining therapies to treat cancer: independent action, response correlation, and collateral sensitivity versus synergy","volume":"7","author":"Schmidt","year":"2023","journal-title":"Ann. Rev. Cancer Biol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189552_bb0080","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.molcel.2020.05.031","article-title":"Rational cancer treatment combinations: an urgent clinical need","volume":"78","author":"Boshuizen","year":"2020","journal-title":"Mol. Cell"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189552_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0326245","article-title":"Multitarget inhibition of CDK2, EGFR, and tubulin by phenylindole derivatives: insights from 3D-QSAR, molecular docking, and dynamics for cancer therapy","volume":"20","author":"Al-Zaydi","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2026.189552_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101510","article-title":"Key signal transduction pathways and crosstalk in cancer: biological and therapeutic opportunities","volume":"26","author":"Fu","year":"2022","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0095","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s42003-022-03016-5","article-title":"Breaking the crosstalk of the cellular tumorigenic network by low-dose combination therapy in lung cancer patient-derived xenografts","volume":"5","author":"G\u00fcrgen","year":"2022","journal-title":"Commun. Biol."},{"issue":"16","key":"10.1016\/j.bbcan.2026.189552_bb0100","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.21037\/atm-21-1948","article-title":"A narrative review of tumor heterogeneity and challenges to tumor drug therapy","volume":"9","author":"Zhu","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.bbcan.2026.189552_bb0105","first-page":"27","article-title":"Acquired resistance to molecularly targeted therapies for cancer","volume":"8","author":"Stubbs","year":"2025","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.bbcan.2026.189552_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103234","article-title":"Combination of HGF\/MET-targeting agents and other therapeutic strategies in cancer","volume":"160","author":"Moosavi","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0115","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","article-title":"Combination strategies to maximize the benefits of cancer immunotherapy","volume":"14","author":"Zhu","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"14","key":"10.1016\/j.bbcan.2026.189552_bb0120","doi-asserted-by":"crossref","first-page":"13417","DOI":"10.1007\/s00432-023-05136-9","article-title":"Targeting cancer stem cells as a strategy for reducing chemotherapy resistance in head and neck cancers","volume":"149","author":"Dorna","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189552_bb0125","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","article-title":"Rational combinations of targeted cancer therapies: background, advances and challenges","volume":"22","author":"Jin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"15","key":"10.1016\/j.bbcan.2026.189552_bb0130","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1182\/bloodadvances.2023010108","article-title":"Cost-effectiveness of targeted treatment vs chemoimmunotherapy in treatment-naive unfit CLL without TP53 aberrations","volume":"7","author":"Slot","year":"2023","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189552_bb0135","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0140","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","article-title":"DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications","volume":"24","author":"Drew","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189552_bb0145","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1158\/2159-8290.CD-22-1220","article-title":"The DNA damage response and inflammation in cancer","volume":"13","author":"Klapp","year":"2023","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189552_bb0150","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s42764-022-00087-w","article-title":"Exploring the DNA damage response pathway for synthetic lethality","volume":"4","author":"Xu","year":"2023","journal-title":"Genome Instab. Dis."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0155","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00018-024-05214-2","article-title":"When DNA-damage responses meet innate and adaptive immunity","volume":"81","author":"Tong","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bbcan.2026.189552_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.666815","article-title":"Targeting DNA damage response pathway in ovarian clear cell carcinoma","volume":"11","author":"Wong","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0165","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","article-title":"DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2026.189552_bb0170","series-title":"Nicotinamide Adenine Dinucleotide and Signaling Transduction. Biology of Nicotinamide Coenzymes: From Basic Science to Clinical Applications","first-page":"239","author":"Xu","year":"2025"},{"key":"10.1016\/j.bbcan.2026.189552_bb0175","series-title":"Targeting the DNA Damage Response for Cancer Therapy","author":"Yap","year":"2023"},{"issue":"12","key":"10.1016\/j.bbcan.2026.189552_bb0180","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.molcel.2022.02.021","article-title":"The expanding universe of PARP1-mediated molecular and therapeutic mechanisms","volume":"82","author":"Huang","year":"2022","journal-title":"Mol. Cell"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189552_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22105112","article-title":"PARP power: a structural perspective on PARP1, PARP2, and PARP3 in DNA damage repair and nucleosome remodelling","volume":"22","author":"van Beek","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"16","key":"10.1016\/j.bbcan.2026.189552_bb0190","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.molcel.2022.06.011","article-title":"Captured snapshots of PARP1 in the active state reveal the mechanics of PARP1 allostery","volume":"82","author":"Rouleau-Turcotte","year":"2022","journal-title":"Mol. Cell"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189552_bb0195","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/ijc.33918","article-title":"PARP mediated DNA damage response, genomic stability and immune responses","volume":"150","author":"Zong","year":"2022","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189552_bb0200","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/sj.emboj.7601015","article-title":"Parp-1 protects homologous recombination from interference by ku and ligase IV in vertebrate cells","volume":"25","author":"Hochegger","year":"2006","journal-title":"EMBO J."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189552_bb0205","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1158\/2159-8290.CD-13-0891","article-title":"PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair","volume":"4","author":"Hu","year":"2014","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189552_bb0210","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189552_bb0215","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1080\/15384101.2019.1617454","article-title":"PARP3 comes to light as a prime target in cancer therapy","volume":"18","author":"Rodriguez-Vargas","year":"2019","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbcan.2026.189552_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1441222","article-title":"Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer","volume":"14","author":"Xie","year":"2024","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189552_bb0225","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3390\/cancers12030739","article-title":"The multifactorial role of PARP-1 in tumor microenvironment","volume":"12","author":"Mart\u00ed","year":"2020","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189552_bb0230","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1158\/1541-7786.MCR-19-0665","article-title":"An emerging regulatory role for the tumor microenvironment in the DNA damage response to double-strand breaks","volume":"18","author":"Lama-Sherpa","year":"2020","journal-title":"Mol. Cancer Res."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189552_bb0235","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.bbcan.2026.189552_bb0240","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1080\/17501911.2025.2548756","article-title":"Epigenetic synthetic lethality as a cancer therapeutic strategy: synergy of experimental and computational approaches","volume":"17","author":"Farina-Morillas","year":"2025","journal-title":"Epigenomics"},{"issue":"17","key":"10.1016\/j.bbcan.2026.189552_bb0245","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1038\/s41388-021-01744-2","article-title":"Exploiting synthetic lethality to target BRCA1\/2-deficient tumors: where we stand","volume":"40","author":"Patel","year":"2021","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0250","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.gendis.2023.02.014","article-title":"Mechanism of PARP inhibitor resistance and potential overcoming strategies","volume":"11","author":"Fu","year":"2024","journal-title":"Genes Dis."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189552_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ijo.2023.5476","article-title":"Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment","volume":"62","author":"Jin","year":"2023","journal-title":"Int. J. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189552_bb0260","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189552_bb0265","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1042\/BST20191092","article-title":"Systems approach to rational combination therapy: PARP inhibitors","volume":"48","author":"Sun","year":"2020","journal-title":"Biochem. Soc. Trans."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189552_bb0270","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3390\/pharmaceutics17060783","article-title":"Innovative approaches in cancer treatment: emphasizing the role of nanomaterials in tyrosine kinase inhibition","volume":"17","author":"Kurillov\u00e1","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbcan.2026.189552_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0782-4","article-title":"Mechanisms of receptor tyrosine kinase activation in cancer","volume":"17","author":"Du","year":"2018","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189552_bb0280","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.3390\/cancers13071685","article-title":"RTK inhibitors in melanoma: from bench to bedside","volume":"13","author":"Sabbah","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189552_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176727","article-title":"Targeting the RAS upstream and downstream signaling pathway for cancer treatment","volume":"979","author":"Hossain","year":"2024","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0290","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3390\/cells9010198","article-title":"Targeting aberrant RAS\/RAF\/MEK\/ERK signaling for cancer therapy","volume":"9","author":"Degirmenci","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0295","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0300","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0305","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-024-01899-w","article-title":"Therapeutic advances of targeting receptor tyrosine kinases in cancer","volume":"9","author":"Tomuleasa","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbo.2015.01.001","article-title":"Receptor tyrosine kinases: characterisation, mechanism of action and therapeutic interests for bone cancers","volume":"4","author":"S\u00e9galiny","year":"2015","journal-title":"J Bone Oncol."},{"key":"10.1016\/j.bbcan.2026.189552_bb0315","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1133472","article-title":"Targeting the BRCA1\/2 deficient cancer with PARP inhibitors: clinical outcomes and mechanistic insights","volume":"11","author":"Ragupathi","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189552_bb0320","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41416-018-0271-y","article-title":"Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy","volume":"119","author":"Friedlander","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189552_bb0325","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2020-001556","article-title":"Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes","volume":"30","author":"Pietragalla","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189552_bb0330","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.3390\/cancers14112640","article-title":"Pharmacologic induction of BRCAness in BRCA-proficient cancers: expanding PARP inhibitor use","volume":"14","author":"Abbotts","year":"2022","journal-title":"Cancers"},{"issue":"6330","key":"10.1016\/j.bbcan.2026.189552_bb0335","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0340","article-title":"Relationships between DNA repair and RTK-mediated signaling pathways","volume":"1875","author":"Chabot","year":"2021","journal-title":"Biochim. Biophys. Acta Revi. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189552_bb0345","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nm.4032","article-title":"Blocking c-met\u2013mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors","volume":"22","author":"Du","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189552_bb0350","series-title":"Targeting the DNA Damage Response for Cancer Therapy","first-page":"171","article-title":"Rational combinations of PARP inhibitors with HRD-inducing molecularly targeted agents","author":"Lee","year":"2023"},{"key":"10.1016\/j.bbcan.2026.189552_bb0355","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/978-3-031-30065-3_10","article-title":"Rational combinations of PARP inhibitors with HRD-inducing molecularly targeted agents","volume":"186","author":"Lee","year":"2023","journal-title":"Cancer Treat. Res."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189552_bb0360","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41416-023-02326-7","article-title":"PARP inhibitors: enhancing efficacy through rational combinations","volume":"129","author":"Bhamidipati","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189552_bb0365","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1080\/14737140.2024.2393251","article-title":"Strategies for the prevention or reversal of PARP inhibitor resistance","volume":"24","author":"Mitri","year":"2024","journal-title":"Expert. Rev. Anticancer. Ther."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189552_bb0370","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3390\/biom13101480","article-title":"Combination treatment strategies to overcome PARP inhibitor resistance","volume":"13","author":"Soung","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.bbcan.2026.189552_bb0375","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13048-023-01094-5","article-title":"Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status","volume":"16","author":"Wu","year":"2023","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.bbcan.2026.189552_bb0380","article-title":"Analysis of 20 independently performed assays to measure homologous recombination deficiency (HRD) in ovarian cancer: findings from the friends\u2019 HRD harmonization project","volume":"1","author":"Andrews","year":"2024","journal-title":"JCO Oncol. Adv."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0385","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1186\/s12885-025-14267-w","article-title":"Pan-cancer analysis of homologous recombination deficiency and homologous recombination repair\u2013associated gene alterations in solid tumors from a large asian cohort","volume":"25","author":"Ren","year":"2025","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0390","article-title":"The emerging role of c-met in carcinogenesis and clinical implications as a possible therapeutic target","volume":"2022","author":"Faiella","year":"2022","journal-title":"J. Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189552_bb0395","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.3390\/cancers17091493","article-title":"Targeting c-MET alterations in cancer: a review of genetic drivers and therapeutic implications","volume":"17","author":"Ji","year":"2025","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189552_bb0400","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3390\/ph17040448","article-title":"The MET oncogene: thirty years of insights into molecular mechanisms driving malignancy","volume":"17","author":"Crepaldi","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bbcan.2026.189552_bb0405","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.92762","article-title":"Recording and classifying MET receptor mutations in cancers","volume":"13","author":"Gu\u00e9rin","year":"2024","journal-title":"eLife"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189552_bb0410","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1038\/s41388-020-01577-5","article-title":"The role of MET in chemotherapy resistance","volume":"40","author":"Wood","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2026.189552_bb0415","series-title":"HGF\/c-Met Signalling in the Tumor Microenvironment. Tumor Microenvironment: Signaling Pathways\u2013Part B","first-page":"31","author":"Zambelli","year":"2021"},{"issue":"28","key":"10.1016\/j.bbcan.2026.189552_bb0420","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1038\/s41388-021-01863-w","article-title":"HGF\/c-MET pathway in cancer: from molecular characterization to clinical evidence","volume":"40","author":"Fu","year":"2021","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189552_bb0425","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11050638","article-title":"Role of c-MET inhibitors in overcoming drug resistance in spheroid models of primary human pancreatic cancer and stellate cells","volume":"11","author":"Firuzi","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2026.189552_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173850","article-title":"Antiproliferative effect, alteration of cancer cell cycle progression and potential MET kinase inhibition induced by 3,4-dihydropyrimidin-2(1H)-one c5 amide derivatives","volume":"894","author":"Moosavi","year":"2021","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189552_bb0435","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/2159-8290.CD-19-1446","article-title":"Targeting MET dysregulation in cancer","volume":"10","author":"Recondo","year":"2020","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0440","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-41283-2","article-title":"Novel quinazoline-1,2,3-triazole hybrids with anticancer and MET kinase targeting properties","volume":"13","author":"Mortazavi","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2026.189552_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175395","article-title":"Discovery of anticancer agents with c-met inhibitory potential by virtual and experimental screening of a chemical library","volume":"938","author":"Mortazavi","year":"2023","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0450","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1038\/s41598-021-83069-4","article-title":"Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-met","volume":"11","author":"Damghani","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2026.189552_bb0455","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.biochi.2024.12.006","article-title":"Combination of chemotherapy and c-MET inhibitors has synergistic effects in c-MET overexpressing pancreatic cancer cells","volume":"231","author":"Moosavi","year":"2024","journal-title":"Biochimie"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0460","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s13205-024-04162-9","article-title":"c-MET tyrosine kinase inhibitors reverse drug resistance mediated by the ATP-binding cassette transporter B1 (ABCB1) in cancer cells","volume":"15","author":"Nazari","year":"2025","journal-title":"3 Biotech"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189552_bb0465","first-page":"608","article-title":"Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells","volume":"9","author":"Han","year":"2019","journal-title":"Am. J. Cancer Res."},{"issue":"65","key":"10.1016\/j.bbcan.2026.189552_bb0470","doi-asserted-by":"crossref","first-page":"6981","DOI":"10.18632\/oncotarget.27363","article-title":"Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer","volume":"10","author":"Sahin","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189552_bb0475","first-page":"4383","article-title":"Targeting c-MET to enhance the efficacy of olaparib in prostate cancer","author":"Wang","year":"2021","journal-title":"Onco. Targets Ther."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189552_bb0480","doi-asserted-by":"crossref","first-page":"47","DOI":"10.14715\/cmb\/2022.68.8.8","article-title":"Antiproliferative effects of EGFR inhibitor cetuximab and PARP inhibitor combination on non-small cell lung cancer cell line a549 and cervical cancer cell line HeLa","volume":"68","author":"\u00c7etin","year":"2022","journal-title":"Cell. Mol. Biol."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189552_bb0485","doi-asserted-by":"crossref","first-page":"7839","DOI":"10.1021\/acs.jmedchem.1c00649","article-title":"Rational design and synthesis of novel dual PROTACs for simultaneous degradation of EGFR and PARP","volume":"64","author":"Zheng","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbcan.2026.189552_bb0490","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1149918","article-title":"The benefit of co-targeting PARP-1 and c-met on the efficacy of radiotherapy in wild type BRAF melanoma","volume":"10","author":"Sabbah","year":"2023","journal-title":"Front. Med."},{"issue":"18","key":"10.1016\/j.bbcan.2026.189552_bb0495","doi-asserted-by":"crossref","first-page":"10420","DOI":"10.1111\/jcmm.15655","article-title":"Inhibition of c-MET increases the antitumour activity of PARP inhibitors in gastric cancer models","volume":"24","author":"Koustas","year":"2020","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0500","first-page":"236","article-title":"Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells","volume":"11","author":"Gao","year":"2021","journal-title":"Am. J. Cancer Res."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189552_bb0505","doi-asserted-by":"crossref","first-page":"5770","DOI":"10.3390\/ijms23105770","article-title":"Cancer cells haploinsufficient for ATM are sensitized to PARP inhibitors by MET inhibition","volume":"23","author":"D\u2019Ambrosio","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0510","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/bab.2104","article-title":"The interplay of ROS and the PI3K\/Akt pathway in autophagy regulation","volume":"69","author":"Kma","year":"2022","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.bbcan.2026.189552_bb0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103749","article-title":"Prospects of targeting PI3K\/AKT\/mTOR pathway in pancreatic cancer","volume":"176","author":"Mortazavi","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"24","key":"10.1016\/j.bbcan.2026.189552_bb0520","doi-asserted-by":"crossref","first-page":"11157","DOI":"10.1111\/jcmm.17037","article-title":"MET inhibition enhances PARP inhibitor efficacy in castration-resistant prostate cancer by suppressing the ATM\/ATR and PI3K\/AKT pathways","volume":"25","author":"Zhou","year":"2021","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0525","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41568-022-00518-6","article-title":"Leveraging the replication stress response to optimize cancer therapy","volume":"23","author":"Cybulla","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0530","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","article-title":"Targeting replication stress in cancer therapy","volume":"22","author":"da Costa","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189552_bb0535","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4103\/AIHB.AIHB_78_19","article-title":"ATM and ATR checkpoint kinase pathways: a concise review","volume":"10","author":"Wagh","year":"2020","journal-title":"Adv. Hum. Biol."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189552_bb0540","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.trecan.2021.06.002","article-title":"Targeting the replication stress response through synthetic lethal strategies in cancer medicine","volume":"7","author":"Ngoi","year":"2021","journal-title":"Trends Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189552_bb0545","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.3390\/ijms25021064","article-title":"Molecular targeting of the human epidermal growth factor receptor-2 (HER2) genes across various cancers","volume":"25","author":"Rubin","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189552_bb0550","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/bs.acr.2020.04.003","article-title":"EGFR: an essential receptor tyrosine kinase-regulator of cancer stem cells","volume":"147","author":"Talukdar","year":"2020","journal-title":"Adv. Cancer Res."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189552_bb0555","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2967\/jnumed.112.111534","article-title":"Treatment of triple-negative breast cancer using anti-EGFR\u2013directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor","volume":"54","author":"Al-Ejeh","year":"2013","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189552_bb0560","first-page":"648","article-title":"Blocking c-met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer","volume":"10","author":"Chu","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189552_bb0565","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.2147\/DDDT.S82035","article-title":"Combination of erlotinib and a PARP inhibitor inhibits growth of a2780 tumor xenografts due to increased autophagy","author":"Sui","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189552_bb0570","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1667\/RR15480.1","article-title":"Combined EGFR1 and PARP1 inhibition enhances the effect of radiation in head and neck squamous cell carcinoma models","volume":"194","author":"Frederick","year":"2020","journal-title":"Radiat. Res."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189552_bb0575","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1158\/0008-5472.CAN-18-1273","article-title":"EGFR and c-MET cooperate to enhance resistance to PARP inhibitors in hepatocellular carcinoma","volume":"79","author":"Dong","year":"2019","journal-title":"Cancer Res."},{"issue":"49","key":"10.1016\/j.bbcan.2026.189552_bb0580","doi-asserted-by":"crossref","first-page":"45665","DOI":"10.1021\/acsomega.2c06531","article-title":"Synthesis of new bioactive indolyl-1, 2, 4-triazole hybrids as dual inhibitors for EGFR\/PARP-1 targeting breast and liver cancer cells","volume":"7","author":"Youssef","year":"2022","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0585","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1039\/D4RA05966B","article-title":"Potent EGFR\/PARP-1 inhibition by spirooxindole-triazole hybrids for targeted liver cancer therapy","volume":"15","author":"Nafie","year":"2025","journal-title":"RSC Adv."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0590","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1186\/s12885-024-13334-y","article-title":"Regorafenib induces DNA damage and enhances PARP inhibitor efficacy in pancreatic ductal carcinoma","volume":"24","author":"Pham","year":"2024","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.bbcan.2026.189552_bb0595","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1016\/j.celrep.2019.05.058","article-title":"Acquired resistance of EGFR-mutated lung cancer to tyrosine kinase inhibitor treatment promotes PARP inhibitor sensitivity","volume":"27","author":"Marcar","year":"2019","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189552_bb0600","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1158\/1078-0432.CCR-19-2549","article-title":"EGFR amplification induces increased DNA damage response and renders selective sensitivity to talazoparib (PARP inhibitor) in glioblastoma","volume":"26","author":"Wu","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189552_bb0605","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s12276-020-0384-2","article-title":"ROS in cancer therapy: the bright side of the moon","volume":"52","author":"Perillo","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0610","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15548627.2015.1100356","article-title":"Guidelines for the use and interpretation of assays for monitoring autophagy","volume":"12","author":"Klionsky","year":"2016","journal-title":"Autophagy"},{"issue":"16","key":"10.1016\/j.bbcan.2026.189552_bb0615","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJMra2022774","article-title":"Autophagy in human diseases","volume":"383","author":"Mizushima","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1\u20132","key":"10.1016\/j.bbcan.2026.189552_bb0620","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cell.2018.09.048","article-title":"Biological functions of autophagy genes: a disease perspective","volume":"176","author":"Levine","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0625","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15548627.2025.2580026","article-title":"Autophagy-mediated quality control of MHC class i molecules regulates tumor evasion","volume":"22","author":"Bhattacharyya","year":"2026","journal-title":"Autophagy"},{"key":"10.1016\/j.bbcan.2026.189552_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101170","article-title":"Autophagy in cancer development, immune evasion, and drug resistance","volume":"78","author":"Niu","year":"2025","journal-title":"Drug Resist. Updat."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189552_bb0635","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bulcan.2020.11.004","article-title":"An overview of autophagy: mechanism, regulation and research progress","volume":"108","author":"Cao","year":"2021","journal-title":"Bull. Cancer"},{"key":"10.1016\/j.bbcan.2026.189552_bb0640","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1528230","article-title":"The role of autophagy in cancer: from molecular mechanism to therapeutic window","volume":"16","author":"Jalali","year":"2025","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189552_bb0645","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/s41416-020-01238-0","article-title":"Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition","volume":"124","author":"Bellare","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189552_bb0650","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/cncr.32600","article-title":"Poly (adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models","volume":"126","author":"Santiago-O\u2019Farrill","year":"2020","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189552_bb0655","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41580-023-00585-z","article-title":"Autophagy and autophagy-related pathways in cancer","volume":"24","author":"Debnath","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"19","key":"10.1016\/j.bbcan.2026.189552_bb0660","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021108863","article-title":"Autophagy in major human diseases","volume":"40","author":"Klionsky","year":"2021","journal-title":"EMBO J."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189552_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2022.166400","article-title":"Role and regulation of autophagy in cancer","volume":"1868","author":"Rakesh","year":"2022","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189552_bb0670","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/15384047.2018.1436024","article-title":"The irreversible ERBB1\/2\/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells","volume":"19","author":"Booth","year":"2018","journal-title":"Cancer Biol. Ther."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189552_bb0675","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046614","article-title":"Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells","volume":"7","author":"Nowsheen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2026.189552_bb0680","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.lungcan.2020.09.018","article-title":"Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)","volume":"150","author":"Garcia-Campelo","year":"2020","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189552_bb0685","article-title":"BRCA1 expression and outcome in patients with EGFR-mutant NSCLC treated with gefitinib alone or in combination with olaparib","volume":"2","author":"Karachaliou","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"issue":"20","key":"10.1016\/j.bbcan.2026.189552_bb0690","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1158\/1078-0432.CCR-18-0467","article-title":"Final report of a phase i trial of olaparib with cetuximab and radiation for heavy smoker patients with locally advanced head and neck cancer","volume":"24","author":"Karam","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0695","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41392-024-02121-7","article-title":"AXL signaling in cancer: from molecular insights to targeted therapies","volume":"10","author":"Yadav","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2026.189552_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.insi.2025.100171","article-title":"A novel framework for assessing large language models in computational drug design: targeting AXL receptor tyrosine kinase for cancer therapy","volume":"2","author":"Shams","year":"2026","journal-title":"In Silico Res. Biomed."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0705","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","article-title":"AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189552_bb0710","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s11912-023-01392-7","article-title":"AXL inhibitors: status of clinical development","volume":"25","author":"Bhalla","year":"2023","journal-title":"Curr. Oncol. Rep."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0715","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13046-023-02726-w","article-title":"AXL in cancer: a modulator of drug resistance and therapeutic target","volume":"42","author":"Tang","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"6954","key":"10.1016\/j.bbcan.2026.189552_bb0720","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/nature01965","article-title":"Control of spontaneous and damage-induced mutagenesis by SUMO and ubiquitin conjugation","volume":"425","author":"Stelter","year":"2003","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0725","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s42003-023-05045-0","article-title":"The effect of inhibition of receptor tyrosine kinase AXL on DNA damage response in ovarian cancer","volume":"6","author":"Yeo","year":"2023","journal-title":"Commun. Biol."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189552_bb0730","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/2159-8290.CD-22-0111","article-title":"AXL and error-prone DNA replication confer drug resistance and offer strategies to treat EGFR-mutant lung cancer","volume":"12","author":"Noronha","year":"2022","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0735","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1158\/0008-5472.CAN-12-3151","article-title":"ABL regulation by AXL promotes cisplatin resistance in esophageal cancer","volume":"73","author":"Hong","year":"2013","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189552_bb0740","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1158\/1541-7786.MCR-20-0414","article-title":"AXL inhibition induces DNA damage and replication stress in non\u2013small cell lung cancer cells and promotes sensitivity to ATR inhibitors","volume":"19","author":"Ramkumar","year":"2021","journal-title":"Mol. Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189552_bb0745","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030466","article-title":"AXL receptor tyrosine kinase as a promising therapeutic target directing multiple aspects of cancer progression and metastasis","volume":"14","author":"Goyette","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0750","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/1541-7786.MCR-16-0157","article-title":"AXL inhibition suppresses the DNA damage response and sensitizes cells to PARP inhibition in multiple cancers","volume":"15","author":"Balaji","year":"2017","journal-title":"Mol. Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189552_bb0755","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1158\/1541-7786.MCR-21-0302","article-title":"GAS6\/AXL inhibition enhances ovarian cancer sensitivity to chemotherapy and PARP inhibition through increased DNA damage and enhanced replication stress","volume":"20","author":"Mullen","year":"2022","journal-title":"Mol. Cancer Res."},{"issue":"17","key":"10.1016\/j.bbcan.2026.189552_bb0760","article-title":"AXL inhibition prevents RPA2\/CHK1-mediated homologous recombination to increase PARP inhibitor sensitivity in hepatocellular carcinoma","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189552_bb0765","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcaa022","article-title":"Replication protein a: A multifunctional protein with roles in DNA replication, repair and beyond","volume":"2","author":"Dueva","year":"2020","journal-title":"NAR Cancer."},{"issue":"24","key":"10.1016\/j.bbcan.2026.189552_bb0770","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415585","article-title":"The VEGF\/VEGFR axis revisited: implications for cancer therapy","volume":"23","author":"Mabeta","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189552_bb0775","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.semcancer.2022.03.011","article-title":"The impact of VEGF on cancer metastasis and systemic disease","volume":"86","author":"Yang","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbcan.2026.189552_bb0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175586","article-title":"The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF","volume":"949","author":"Ghalehbandi","year":"2023","journal-title":"Eur. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189552_bb0785","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.3390\/biom10121673","article-title":"Structural basis for vascular endothelial growth factor receptor activation and implications for disease therapy","volume":"10","author":"Shaik","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.bbcan.2026.189552_bb0790","article-title":"Molecular bases of VEGFR-2-mediated physiological function and pathological role","volume":"8","author":"Wang","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189552_bb0795","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.3390\/ijms23063375","article-title":"Relationship between VEGF family members, their receptors and cell death in the neoplastic transformation of colorectal cancer","volume":"23","author":"Dakowicz","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189552_bb0800","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01196-x","article-title":"VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status","volume":"14","author":"Bizzaro","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189552_bb0805","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.oraloncology.2014.03.006","article-title":"Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells","volume":"50","author":"Hsu","year":"2014","journal-title":"Oral Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189552_bb0810","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207399","article-title":"Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer","volume":"13","author":"Lin","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2026.189552_bb0815","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1302850","article-title":"Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K\/AKT pathway","volume":"14","author":"Iida","year":"2024","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189552_bb0820","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14051776","article-title":"Efficacy and safety of combination therapy with PARP inhibitors and anti-Angiogenic agents in ovarian cancer: a systematic review and meta-analysis","volume":"14","author":"Barad\u00e1cs","year":"2025","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0825","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1186\/s12967-025-06702-0","article-title":"The roles of cryptochrome-1: the circadian clock as a control point in cancer therapy","volume":"23","author":"Liu","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bbcan.2026.189552_bb0830","article-title":"FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer","volume":"1-24","author":"Tai","year":"2024","journal-title":"EMBO Mol. Med."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189552_bb0835","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/CAD.0000000000001631","article-title":"Donafenib inhibits PARP1 expression and induces DNA damage, in combination with PARP1 inhibitors promotes apoptosis in liver cancer cells","volume":"35","author":"Jiang","year":"2024","journal-title":"Anti-Cancer Drugs"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0840","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1038\/s41467-024-45974-w","article-title":"Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: A phase II clinical trial from the GINECO group","volume":"15","author":"Freyer","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189552_bb0845","first-page":"35","article-title":"A single-arm, phase II study of niraparib and bevacizumab maintenance in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor (KGOG 3056\/NIRVANA-R)","author":"Lee","year":"2024","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189552_bb0850","series-title":"Biomarker Results from the KGOG3056\/NIRVANA-R Trial: Maintenance Niraparib plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian cancer Previously Treated with a PARP Inhibitor","author":"Cho","year":"2025"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189552_bb0855","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41416-023-02567-6","article-title":"Results of a randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer","volume":"130","author":"Nicum","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0860","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1158\/1078-0432.CCR-23-2249","article-title":"Olaparib plus durvalumab, with or without bevacizumab, as treatment in PARP inhibitor-na\u00efve platinum-sensitive relapsed ovarian cancer: a phase II multi-cohort study","volume":"30","author":"Drew","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189552_bb0865","volume":"34","author":"Lorusso","year":"2024","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0870","doi-asserted-by":"crossref","first-page":"5476","DOI":"10.1038\/s41467-023-40829-2","article-title":"Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01\/APGOT-OV4","volume":"14","author":"Kim","year":"2023","journal-title":"Nat. Commun."},{"issue":"19","key":"10.1016\/j.bbcan.2026.189552_bb0875","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.21.02011","article-title":"Olaparib with or without cediranib versus platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (NRG-GY004): a randomized, open-label, phase III trial","volume":"40","author":"Liu","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.bbcan.2026.189552_bb0880","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1158\/1078-0432.CCR-21-1733","article-title":"Cediranib in combination with olaparib in patients without a germline BRCA1\/2 mutation and with recurrent platinum-resistant ovarian cancer: phase IIb CONCERTO trial","volume":"28","author":"Lee","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189552_bb0885","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ygyno.2022.01.015","article-title":"Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer","volume":"164","author":"Colombo","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189552_bb0890","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.21.02947","article-title":"Randomized trial of olaparib with or without cediranib for metastatic castration-resistant prostate cancer: the results from national cancer institute 9984","volume":"41","author":"Kim","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189552_bb0895","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.35151","article-title":"NRG-GY012: randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib\/olaparib in women with recurrent, persistent, or metastatic endometrial cancer","volume":"130","author":"Rimel","year":"2024","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189552_bb0900","doi-asserted-by":"crossref","first-page":"e1104","DOI":"10.1002\/onco.13758","article-title":"Clinical activity and safety of cediranib and olaparib combination in patients with metastatic pancreatic ductal adenocarcinoma without BRCA mutation","volume":"26","author":"Kim","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2026.189552_bb0905","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0680-3","article-title":"A phase i study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1\u20133 inhibitor, cediranib, in recurrent womens cancers with biomarker analyses","volume":"7","author":"Zimmer","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189552_bb0910","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/bjc.2011.555","article-title":"Phase i study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours","volume":"106","author":"Dean","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189552_bb0915","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1158\/1535-7163.MCT-10-0615","article-title":"Targeting oncogenic ALK: A promising strategy for cancer treatment","volume":"10","author":"Grande","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0920","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a001115","article-title":"ALK: A tyrosine kinase target for cancer therapy","volume":"3","author":"Holla","year":"2017","journal-title":"Mol. Case Stud."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189552_bb0925","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1158\/1541-7786.MCR-23-0680","article-title":"Crizotinib enhances PARP inhibitor efficacy in ovarian cancer cells and xenograft models by inducing autophagy","volume":"22","author":"Santiago-O\u2019Farrill","year":"2024","journal-title":"Mol. Cancer Res."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189552_bb0930","first-page":"1211","article-title":"Targeting the ALK\u2013CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex","volume":"3","author":"Chu","year":"2022","journal-title":"Nat. Can."},{"issue":"17","key":"10.1016\/j.bbcan.2026.189552_bb0935","doi-asserted-by":"crossref","first-page":"11135","DOI":"10.1128\/JVI.79.17.11135-11141.2005","article-title":"Ubiquitylation of cdk9 by skp2 facilitates optimal tat transactivation","volume":"79","author":"Barboric","year":"2005","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189552_bb0940","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1158\/0008-5472.CAN-21-0732","article-title":"Repurposing ceritinib induces DNA damage and enhances PARP inhibitor responses in high-grade serous ovarian carcinoma","volume":"82","author":"Kanakkanthara","year":"2022","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0945","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.gendis.2022.03.002","article-title":"Drugging IGF-1R in cancer: new insights and emerging opportunities","volume":"10","author":"Wang","year":"2023","journal-title":"Genes Dis."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189552_bb0950","doi-asserted-by":"crossref","first-page":"6","DOI":"10.30699\/mci.6.4.32-5","article-title":"A review of the molecular mechanisms of EGFR and IGFR receptors in tamoxifen resistance in breast cancer","volume":"6","author":"Mansouri","year":"2022","journal-title":"Multidisc. Cancer Invest."},{"key":"10.1016\/j.bbcan.2026.189552_bb0955","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-015-1803-y","article-title":"Suppression of homologous recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors","volume":"15","author":"Amin","year":"2015","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189552_bb0960","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ygyno.2009.07.009","article-title":"BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide","volume":"115","author":"Beauchamp","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb0965","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23010048","article-title":"Ribosomal protein s6: A potential therapeutic target against cancer?","volume":"23","author":"Yi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189552_bb0970","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ijbiomac.2022.01.113","article-title":"Targeting the PDGF\/PDGFR signaling pathway for cancer therapy: a review","volume":"202","author":"Zou","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"issue":"492","key":"10.1016\/j.bbcan.2026.189552_bb0975","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav4508","article-title":"Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1\/2 and RAD51","volume":"11","author":"Kaplan","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbcan.2026.189552_bb0980","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bcp.2018.10.011","article-title":"Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors","volume":"167","author":"Mukhopadhyay","year":"2019","journal-title":"Biochem. Pharmacol."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189552_bb0985","doi-asserted-by":"crossref","first-page":"490","DOI":"10.20892\/j.issn.2095-3941.2023.0137","article-title":"Current progress in cancer treatment by targeting FGFR signaling","volume":"20","author":"Du","year":"2023","journal-title":"Cancer Biol. Med."},{"issue":"23","key":"10.1016\/j.bbcan.2026.189552_bb0990","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41388-023-02705-7","article-title":"Biological and clinical implications of FGFR aberrations in paediatric and young adult cancers","volume":"42","author":"Brown","year":"2023","journal-title":"Oncogene"},{"issue":"18","key":"10.1016\/j.bbcan.2026.189552_bb0995","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.3390\/ijms21186856","article-title":"FGFR fusions in cancer: from diagnostic approaches to therapeutic intervention","volume":"21","author":"De Luca","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.bbcan.2026.189552_bb1000","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173757","article-title":"FGFR3-induced y158 PARP1 phosphorylation promotes PARP-inhibitor resistance via BRG1\/MRE11-mediated DNA repair in breast cancer models","volume":"135","author":"Chen","year":"2025","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189552_bb1005","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3390\/cells9040911","article-title":"Targeted PARP inhibition combined with FGFR1 blockade is synthetically lethal to malignant cells in patients with pancreatic cancer","volume":"9","author":"Lai","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2026.189552_bb1010","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.748149","article-title":"Targeting autophagy with natural compounds in cancer: a renewed perspective from molecular mechanisms to targeted therapy","volume":"12","author":"Xie","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189552_bb1015","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107099","article-title":"Natural products for combating multidrug resistance in cancer","volume":"202","author":"Chen","year":"2024","journal-title":"Pharmacol. Res."},{"issue":"14","key":"10.1016\/j.bbcan.2026.189552_bb1020","doi-asserted-by":"crossref","DOI":"10.3390\/cells11142209","article-title":"The role of natural products and their multitargeted approach to treat solid cancer","volume":"11","author":"Muhammad","year":"2022","journal-title":"Cells"},{"issue":"4\u20136","key":"10.1016\/j.bbcan.2026.189552_bb1025","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1089\/ars.2023.0445","article-title":"Reactive oxygen species modulation in the current landscape of anticancer therapies","volume":"41","author":"Li","year":"2024","journal-title":"Antioxid. Redox Signal."},{"issue":"38","key":"10.1016\/j.bbcan.2026.189552_bb1030","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.2174\/0929867330666230112092802","article-title":"Curcumin combats against gastrointestinal cancer: a review of current knowledge regarding epigenetics mechanisms with a focus on DNA methylation","volume":"30","author":"Jafari-Nozad","year":"2023","journal-title":"Curr. Med. Chem."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189552_bb1035","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/17460441.2025.2507382","article-title":"The latest advances with natural products in drug discovery and opportunities for the future: A 2025 update","volume":"20","author":"Xie","year":"2025","journal-title":"Expert Opin. Drug Discov."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189552_bb1040","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1021\/acsomega.3c06110","article-title":"4\u2033-alkyl EGCG derivatives induce cytoprotective autophagy response by inhibiting EGFR in glioblastoma cells","volume":"9","author":"Singh","year":"2024","journal-title":"ACS Omega"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189552_bb1045","doi-asserted-by":"crossref","DOI":"10.3390\/cimb47090716","article-title":"Revisiting curcumin in cancer therapy: recent insights into molecular mechanisms, nanoformulations, and synergistic combinations","volume":"47","author":"Akter","year":"2025","journal-title":"Curr. Issues Mol. Biol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189552_bb1050","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3892\/ijo.2012.1325","article-title":"Resveratrol induces apoptosis via ROS-triggered autophagy in human colon cancer cells","volume":"40","author":"Miki","year":"2012","journal-title":"Int. J. Oncol."},{"issue":"41","key":"10.1016\/j.bbcan.2026.189552_bb1055","doi-asserted-by":"crossref","first-page":"66944","DOI":"10.18632\/oncotarget.11396","article-title":"Berberine induces autophagy in glioblastoma by targeting the AMPK\/mTOR\/ULK1-pathway","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189552_bb1060","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.3389\/fphar.2019.01336","article-title":"Molecular mechanisms of action of genistein in cancer: recent advances","volume":"10","author":"Tuli","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189552_bb1065","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.598174","article-title":"Natural compounds that target DNA repair pathways and their therapeutic potential to counteract cancer cells","volume":"10","author":"Lagunas-Rangel","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb1070","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12032-025-03140-2","article-title":"The golden touch: A comprehensive network pharmacology-guided review of synergy between curcumin and PARP inhibitors","volume":"43","author":"Khanehzar","year":"2025","journal-title":"Med. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb1075","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2022.113338","article-title":"Olaparib enhances the resveratrol-mediated apoptosis in breast cancer cells by inhibiting the homologous recombination repair pathway","volume":"420","author":"Sinha","year":"2022","journal-title":"Exp. Cell Res."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189552_bb1080","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s12032-023-02279-0","article-title":"Combination of resveratrol and PARP inhibitor olaparib efficiently deregulates homologous recombination repair pathway in breast cancer cells through inhibition of TIP60-mediated chromatin relaxation","volume":"41","author":"Sinha","year":"2024","journal-title":"Med. Oncol."},{"issue":"15","key":"10.1016\/j.bbcan.2026.189552_bb1085","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26157350","article-title":"Combination therapy using phytochemicals and PARP inhibitors in hybrid nanocarriers: an optimistic approach for the management of colon cancer","volume":"26","author":"Qureshi","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189552_bb1090","article-title":"Olaparib has synergistic effects with DNA damaging agents in pancreatic ductal adenocarcinoma","volume":"795","author":"Hassani","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189552_bb1095","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","article-title":"Poly (ADP-ribose) polymerase inhibition: past, present and future","volume":"19","author":"Curtin","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189552_bb1100","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1021\/acs.jmedchem.4c00077","article-title":"Rational design of PARP1\/c-met dual inhibitors for overcoming PARP1 inhibitor resistance induced by c-met overexpression","volume":"67","author":"Sun","year":"2024","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189552_bb1105","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.celrep.2016.03.070","article-title":"PARP inhibition suppresses growth of EGFR-mutant cancers by targeting nuclear PKM2","volume":"15","author":"Li","year":"2016","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189552_bb1110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024148","article-title":"Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer","volume":"6","author":"Nowsheen","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2026.189552_bb1115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-021-01315-9","article-title":"PARP inhibitor olaparib overcomes sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma","volume":"20","author":"Yang","year":"2021","journal-title":"Mol. Cancer"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189552_bb1120","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.neo.2020.06.001","article-title":"Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer","volume":"22","author":"Zhong","year":"2020","journal-title":"Neoplasia"},{"key":"10.1016\/j.bbcan.2026.189552_bb1125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114036","article-title":"Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: the randomized phase 3 LYNK-003 study","volume":"205","author":"Takashima","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189552_bb1130","article-title":"Niraparib, dostarlimab, and bevacizumab as combination therapy in pretreated, advanced platinum-resistant ovarian cancer: findings from cohort a of the OPAL phase II trial","volume":"8","author":"Liu","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.bbcan.2026.189552_bb1135","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ygyno.2024.05.002","article-title":"A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib","volume":"187","author":"Liu","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb1140","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/s12916-023-03046-8","article-title":"A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis","volume":"21","author":"Liu","year":"2023","journal-title":"BMC Med."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189552_bb1145","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ygyno.2021.12.016","article-title":"Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial","volume":"164","author":"Harter","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189552_bb1150","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejca.2022.11.029","article-title":"Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged\u2265 65 years from the PAOLA-1\/ENGOT-ov25 trial","volume":"181","author":"Sabatier","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189552_bb1155","doi-asserted-by":"crossref","first-page":"S511","DOI":"10.1016\/j.annonc.2023.09.1925","volume":"34","author":"Lee","year":"2023","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb1160","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ygyno.2022.04.016","article-title":"A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium","volume":"166","author":"Jackson","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189552_bb1165","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ygyno.2022.05.020","article-title":"OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab","volume":"166","author":"Hardesty","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189552_bb1170","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11523-020-00780-4","article-title":"Phase i study of rucaparib in combination with bevacizumab in ovarian cancer patients: maximum tolerated dose and pharmacokinetic profile","volume":"16","author":"Lorusso","year":"2021","journal-title":"Target. Oncol."},{"issue":"16","key":"10.1016\/j.bbcan.2026.189552_bb1175","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1158\/1078-0432.CCR-19-4121","article-title":"EVOLVE: A multicenter open-label single-arm clinical and translational phase II trial of cediranib plus olaparib for ovarian cancer after PARP inhibition progression","volume":"26","author":"Lheureux","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb1180","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ygyno.2020.01.018","article-title":"A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous\/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer","volume":"157","author":"Cadoo","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189552_bb1185","series-title":"Phase I Study of Fluzoparib, a PARP1 Inhibitor in Combination with Apatinib and Paclitaxel in Patients (Pts) with Advanced Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma","author":"Xu","year":"2019"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189552_bb1190","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/annonc\/mdz018","article-title":"Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer","volume":"30","author":"Liu","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2026.189552_bb1195","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00280-019-03917-z","article-title":"A phase i study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1\/ENGOT-OV24","volume":"84","author":"Mirza","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189552_bb1200","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(19)30515-7","article-title":"Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2\/ENGOT-ov24): a randomised, phase 2, superiority trial","volume":"20","author":"Mirza","year":"2019","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189552_bb1205","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: A randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncol."},{"issue":"21","key":"10.1016\/j.bbcan.2026.189552_bb1210","doi-asserted-by":"crossref","first-page":"34405","DOI":"10.18632\/oncotarget.14907","article-title":"Curcumin blocks autophagy and activates apoptosis of malignant mesothelioma cell lines and increases the survival of mice intraperitoneally transplanted with a malignant mesothelioma cell line","volume":"8","author":"Masuelli","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb1215","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13046-017-0513-5","article-title":"Curcumin suppresses gastric tumor cell growth via ROS-mediated DNA polymerase \u03b3 depletion disrupting cellular bioenergetics","volume":"36","author":"Wang","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189552_bb1220","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.772510","article-title":"Receptor tyrosine kinases and their signaling pathways as therapeutic targets of curcumin in cancer","volume":"12","author":"Sudhesh Dev","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189552_bb1225","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12935-019-0762-9","article-title":"Epigallocatechin-3-gallate inhibits the growth and increases the apoptosis of human thyroid carcinoma cells through suppression of EGFR\/RAS\/RAF\/MEK\/ERK signaling pathway","volume":"19","author":"Wu","year":"2019","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bbcan.2026.189552_bb1230","doi-asserted-by":"crossref","first-page":"8601","DOI":"10.2147\/OTT.S213043","article-title":"Resveratrol as a natural regulator of autophagy for prevention and treatment of cancer","volume":"12","author":"Tian","year":"2019","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.bbcan.2026.189552_bb1235","article-title":"Resveratrol sensitizes breast cancer to PARP inhibitor, talazoparib through dual inhibition of AKT and autophagy flux","volume":"199","author":"Bellare","year":"2022","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb1240","article-title":"Quercetin promotes apoptosis of gastric cancer cells through the EGFR-ERK signaling pathway","volume":"2024","author":"Liu","year":"2024","journal-title":"J. Food Biochem."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189552_bb1245","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.467","article-title":"Regulation of autophagy by polyphenolic compounds as a potential therapeutic strategy for cancer","volume":"5","author":"Hasima","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189552_bb1250","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1077531","article-title":"The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: an update","volume":"14","author":"Lotfi","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb1255","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/ph16010092","article-title":"Targeting the interplay of autophagy and ROS for cancer therapy: an updated overview on phytochemicals","volume":"16","author":"Dong","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb1260","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/13880209.2025.2469607","article-title":"Mechanism of action of genistein on breast cancer and differential effects of different age stages","volume":"63","author":"Xiang","year":"2025","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.bbcan.2026.189552_bb1265","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110245","article-title":"Berberine represses human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK\/mTOR\/p70S6K and akt signaling pathways","volume":"128","author":"Zhang","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbcan.2026.189552_bb1270","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109794","article-title":"Berberine associated photodynamic therapy promotes autophagy and apoptosis via ROS generation in renal carcinoma cells","volume":"123","author":"Lopes","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"46","key":"10.1016\/j.bbcan.2026.189552_bb1275","doi-asserted-by":"crossref","first-page":"76076","DOI":"10.18632\/oncotarget.12589","article-title":"Berberine inhibits EGFR signaling and enhances the antitumor effects of EGFR inhibitors in gastric cancer","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189552_bb1280","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/13880209.2018.1548627","article-title":"Berberine inhibits angiogenesis in glioblastoma xenografts by targeting the VEGFR2\/ERK pathway","volume":"56","author":"Jin","year":"2018","journal-title":"Pharm. Biol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189552_bb1285","doi-asserted-by":"crossref","first-page":"216","DOI":"10.15430\/JCP.2016.21.4.216","article-title":"Role of apigenin in cancer prevention via the induction of apoptosis and autophagy","volume":"21","author":"Sung","year":"2016","journal-title":"J. Cancer Prev."},{"key":"10.1016\/j.bbcan.2026.189552_bb1290","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13578-017-0179-x","article-title":"Apigenin in cancer therapy: anti-cancer effects and mechanisms of action","volume":"7","author":"Yan","year":"2017","journal-title":"Cell Biosci."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189552_bb1295","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3892\/ijmm.2014.1804","article-title":"Axl receptor tyrosine kinase is a novel target of apigenin for the inhibition of cell proliferation","volume":"34","author":"Kim","year":"2014","journal-title":"Int. J. Mol. Med."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26000247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26000247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:44:21Z","timestamp":1780605861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26000247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":259,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0304419X26000247"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189552","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expanding the therapeutic applications of PARP inhibitors in cancer by targeting receptor tyrosine kinases","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189552","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189552"}}